NEW YORK, Oct. 10 - Variagenics said today it granted nonexclusive commercialization rights to ARUP Laboratories to develop a home brew test for an allele associated with risk for cardiovascular disease.
Variations in the human methylenetetrahydrofolate reductase gene are associated with increased risk for cardiovascular disease, central nervous system disorders, osteoporosis, disorders influenced by folic acid metabolism, and cancer, according to Variagenics.
Financial details of the agreement with ARUP, a full-service clinical reference laboratory based in
Variagenics obtained patent rights for the MTHFR gene in 1999 from
Click here for more information.